A Double-Blind, Randomized, Placebo- and Active Comparator-Controlled, 4-Week Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of JNJ-41443532 in Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2014
At a glance
- Drugs JNJ 41443532 (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 10 Jun 2017 Biomarkers information updated
- 01 Nov 2011 Actual initiation date changed from Dec 2010 to Nov 2010 as reported by ClinicalTrials.gov.
- 21 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.